Researchers from the Medical Research Council (MRC) Centre for Regenerative Medicine at the University of Edinburgh have identified the cells responsible for a form of leukaemia that can develop while a baby is in the womb.
The research, published in Cell Reports, adds to our knowledge of how this aggressive type of cancer advances and will help identify future therapies.
One form of leukaemia is caused by a type of DNA damage called ‘chromosomal translocation’. This is where parts of two different chromosomes fuse together. The resultant fusion gene – in this instance MLL-AF4 – acts in a very different way from when the two genes are separate.
The expression of the MLL4-AF4 fusion gene can occur at very early stages of the embryo’s development while in the womb and can result in infants being born with a very aggressive form of leukaemia. The earlier the onset of this form of blood cancer, the worse the prognosis.
Survival rates for the most common form of childhood leukaemia, acute lymphoblastic leukaemia (ALL) have improved dramatically, with around nine in 10 children surviving for longer than five years. Infant ALL, which develops when the child is under 12 months of age, accounts for less than five percent of cases of childhood ALL and is a biologically distinct cancer – often involving just a few genetic faults. It has a much poorer outlook, with only around half of patients surviving for longer than five years. A MLL gene fault is involved in 80% of cases of infant acute lymphoblastic leukaemia.
Because this cancer begins to develop ”in utero” and prior studies have studied the effect of MLL-AF4 in blood cells of adult mice only, the key question of how MLL-AF4 might affect an unborn baby’s unique blood cells remained unanswered. This is the first study to investigate how MLL-AF4 effects developing blood forming cells in mouse embryos in a bid to understand how this aggressive leukaemia emerges.
To investigate the disease process, scientists bred mice where one parent carries an inactive form of the fusion gene and the other parent expresses a gene for an enzyme that activates the fusion gene. The embryos from this pairing were found to have a development window where a pre-leukaemic state took hold with increased production of pro-B cells – precursor to a type of white blood cell.
Lead researcher, Dr Katrin Ottersbach, said of the results:
One of the most common and aggressive types of infant blood cancer is associated with the MLL-AF4 fusion gene, which arises during pregnancy. One of the main impediments to improving the survival rates in infants is the lack of knowledge on where and when during development this mutation arises and how it affects the developing blood system of the baby.
Our findings reveal the first changes that take place in blood development caused by the MLL-AF4 mutation during a pre-cancerous state. This has increased our knowledge on how this aggressive disease develops and will help identify early signs of disease and points for therapeutic intervention.
Long term survival rates for childhood leukaemia have improved significantly overall, but the outlook for infants who develop leukaemia soon after birth remains comparatively poor. The intensive chemotherapy used can itself be fatal for babies and many survivors will develop health problems in later life. This more detailed understanding of how a key genetic fault drives the majority of infant leukaemia cases could lead to more effective and kinder treatments in the future.
Barrett NA*, Malouf C*, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SEW, Huntly BJ, Ottersbach K*. 2016. Mll-AF4 confers enhanced self-renewal and lymphoid potential during a restricted window in development. Cell Reports. Epub date 07 July 2016. * Dr Katrin Ottersbach was lead author of the study and Neil Barrett and Camille Malouf were both co-first authors.
For further information or to request an interview with one of the researchers, please contact the MRC press office on 0207 395 2345 or email firstname.lastname@example.org
The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. www.mrc.ac.uk